Download PDF
Klin Padiatr 2010; 222(2): 56-61
DOI: 10.1055/s-0029-1243614
Übersichtsartikel

© Georg Thieme Verlag KG Stuttgart · New York

Stellenwert der Inhalation von Stickstoffmonoxid (NO) bei Frühgeborenen<34 Gestationswochen

Significance of Nitric Oxide Inhalation (NO) in Preterm Infants<34 weeks of GestationJ. Wirbelauer1 , C. P. Speer1
  • 1University Hospital, University Children's Hospital, Würzburg, Germany
Further Information

Publication History

Publication Date:
19 February 2010 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

In Europa wurde inhalatives NO (iNO) Ende 2001 als Medikament zur Behandlung der pulmonalen Hypertension beim reifen Neugeborenen und älteren Frühgeborenen >34 Gestationswochen zugelassen. INO scheint auch bei einem Teil der Frühgeborenen <34 Gestationswochen eine Hypoxämie verbessern zu können. In insgesamt 21 randomisiert-kontrollierten Studien wurden 3 336 Frühgeborene <34 Gestationswochen eingeschlossen. Die Behandlung mit iNO reduziert jedoch weder die Sterblichkeit noch die Rate der bronchopulmonalen Dysplasie (BPD). Auch das kombinierte Risiko aus Tod und BPD wird durch die iNO-Behandlung in dieser Altersgruppe für Frühgeborene mit einem manifesten Lungenversagen oder einem erhöhten BPD-Risiko nicht verändert. Möglicherweise kann eine frühe prophylaktische iNO-Gabe bei Atemstörung die Rate der Frühgeborenen erhöhen, welche ohne BPD, intraventrikuläre Blutungen ≥ III. Grades oder periventrikuläre Leukomalazie überleben. Aufgrund der derzeitigen Datenlage kann die Behandlung Frühgeborener <34 Gestationswochen mit iNO außerhalb randomisiert-kontrollierter Studien nicht empfohlen werden.

Abstract

In 2001, NO was approved as a therapeutic agent in Europe for the treatment of persistent pulmonary hypertension in late preterm infants >34 weeks of gestational age and term newborns. Recent observational studies suggest, that preterm infants <34 weeks of gestation with acute hypoxic lung failure could benefit from inhaled NO (iNO) by improved oxygenation. To date, 21 randomised-controlled trials have enrolled 3 336 preterm infants <34 weeks of gestation for iNO treatment. Overall, iNO treatment does not reduce the rate of bronchopulmonary dysplasia (BPD) or death compared to controls. In addition, iNO treatment of preterm infants with hypoxic respiratory failure or increased risk of BPD does not affect the combined incidence of death and BPD. However, early prophylactic use of iNO in preterm infants with respiratory distress seems to improve survival without BPD or severe cerebral damage. Current data of long term neurological outcome of iNO-treated preterm infants do not seem to justify iNO administration. Outside of well designed clinical trials iNO-treatment of preterm infants can currently not be recommended.

Schlüsselwürter

Frühgeborene - inhalatives Stickstoffmonoxid - Atemnotsyndrom - bronchopulmonale Dysplasie

Key words

preterm infant - nitric oxide - respiratory distress syndrome - bronchopulmonary dysplasia

Literatur

  • 1 Afshar S. et al . Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease.  Am J Physiol Lung Cell Mol Physiol. 2003;  284 L749-L758
    PubMedGoogle Scholar
  • 2 Ahluwalia J. et al . A dose response study of inhaled nitric oxide in hypoxic respiratory failure in preterm infants.  Early Hum Dev. 2006;  82 477-483
    CrossrefPubMedGoogle Scholar
  • 3 Andrews WW. et al . Early preterm birth: association between in utero exposure to acute inflammation and severe neurodevelopmental disability at 6 years of age.  Am J Obstet Gynecol. 2008;  198 466.e1-466.e11
    PubMedGoogle Scholar
  • 4 Arul N, Konduri GG. Inhaled nitric oxide for preterm neonates.  Clin Perinatol. 2009;  36 43-61
    CrossrefPubMedGoogle Scholar
  • 5 Ballard RA. et al . Inhaled nitric oxide in preterm infants undergoing mechanical ventilation.  NEJM. 2006;  355 343-353
    CrossrefPubMedGoogle Scholar
  • 6 Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants (Review).  Cochrane Database Syst Rev. 2007;  18 CD000509
    PubMedGoogle Scholar
  • 7 Bennett AJ. et al . Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide.  Acta Paediatr. 2001;  90 573-576
    PubMedGoogle Scholar
  • 8 Chock VY. et al . Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnions, and pulmonary hypoplasia.  Am J Perinatol. 2009;  26 317-322
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 DŽAlquen D. et al . Activation of umbilical cord endothelial cells and fetal inflammatory response in preterm infants with chorioamnionitis and funisitis.  Pediatr Res. 2005;  57 263-269
    CrossrefPubMedGoogle Scholar
  • 10 Dani C. et al . Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome.  Acta Paediatr. 2006;  95 1116-1123
    CrossrefPubMedGoogle Scholar
  • 11 Day RW. et al . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension.  Pediatrics. 1996;  98 698-705
    PubMedGoogle Scholar
  • 12 Di Fiore JM. et al . The effect of inhaled nitric oxide on pulmonary function in preterm infants.  J Perinatol. 2007;  27 766-771
    CrossrefPubMedGoogle Scholar
  • 13 Field D. et al . Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infantswith severe respiratory failure: the INNOVO multicentre randomised controlled trial.  Pediatrics. 2005;  115 926-936
    CrossrefPubMedGoogle Scholar
  • 14 Gutierrez HH. et al . Nitric oxide regulation of superoxide-dependent lung injury: oxidant protective actions of endogenously produced and exogenously administered nitric oxide.  Free Radic Biol Med. 1996;  21 43-52
    CrossrefPubMedGoogle Scholar
  • 15 Hascoet JM. et al . The safety and efficacy of nitric oxide therapy in premature infants.  J Pediatr.. 2005;  146 318-323
    CrossrefPubMedGoogle Scholar
  • 16 Hibbs AM. et al . One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial.  J Pediatr. 2008;  153 525-529
    PubMedGoogle Scholar
  • 17 Huddy CL. et al . for the INNOVO Trial collaborating group.  Arch Dis Child Fetal Neonatal Ed. 2008;  83 F430-F435
    PubMedGoogle Scholar
  • 18 Issa A. et al . Inhaled nitric oxide decreases hyperoxia-induced surfactant abnormality in preterm rabbits.  Pediatr Res. 1999;  45 247-254
    CrossrefPubMedGoogle Scholar
  • 19 Kinsella JP. et al . Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial.  Lancet. 1999;  354 1061-1065
    Google Scholar
  • 20 Kinsella JP. et al . Early inhaled nitric oxide therapy in premature newborns with respiratory failure.  NEJM. 2006;  355 354-364
    CrossrefPubMedGoogle Scholar
  • 21 Kramer BW. et al . Decreased expression of angiogenic factors in placentas with chorioamnionitis after preterm birth.  Pediatr Res. 2005;  58 607-612
    CrossrefPubMedGoogle Scholar
  • 22 Lavallee M. et al . Crosstalk between endothelin and nitric oxide in the control of vascular tone.  Heart Fail Rev. 2001;  6 265-276
    CrossrefPubMedGoogle Scholar
  • 23 Lindner U. et al . Drug utilisation in very preterm infants: any changes during the past decade?.  Klin Padiatr. 2008;  220 238-242
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Lindwall R. et al . A pilot study of inhaled nitric oxide in preterm infants treated with nasal continous positive airwaypressure for respiratory distress syndrome.  Intensive Care Med. 2005;  31 959-964
    CrossrefPubMedGoogle Scholar
  • 25 McCurnin DC. et al . Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease.  Am J Physiol Lung Cell Mol Physiol. 2005;  288 L450-L459
    CrossrefPubMedGoogle Scholar
  • 26 Mercier JC. et al . for the Franco-Belgium collaborative NO trial group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial.  Lancet. 1999;  354 1066-1071
    CrossrefPubMedGoogle Scholar
  • 27 Mercier JC. et al . Inhaled nitric oxide to prevent bronchopulmonary dysplasia in preterm neonates.  Semin Fetal Neonatal Med. 2009;  14 28-34
    CrossrefPubMedGoogle Scholar
  • 28 Mestan KK. et al . Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide.  N Engl J Med. 2005;  353 23-32
    CrossrefPubMedGoogle Scholar
  • 29 Pearson DL. et al . Neonatal pulmonary hypertension.  New Engl J Med. 2001;  344 1832-1838
    CrossrefPubMedGoogle Scholar
  • 30 Phatak RS. et al . Heliox with inhaled nitric oxide: a novel strategy for severe localized interstitial pulmonary emphysema in preterm neonatal ventilation.  Respir Care. 2008;  53 1731-1738
    PubMedGoogle Scholar
  • 31 Schmidt B. et al . Chorioamnionitis and inflammation of the fetal lung.  Am J Obstet Gynecol. 2001;  185 173-177
    CrossrefPubMedGoogle Scholar
  • 32 Schreiber MD. et al . Inhaled nitric oxide in premature infants with the respiratory distress syndrome.  New Engl J Med. 2003;  349 2099-2107
    CrossrefPubMedGoogle Scholar
  • 33 Shaul PW. Nitric oxide in the developing lung.  Adv Pediatr. 1995;  42 367-414
    PubMedGoogle Scholar
  • 34 Skimming JW. et al . Nitric oxide inhalation in infants with respiratory distress syndrome.  J Pediatr. 1997;  130 225-230
    PubMedGoogle Scholar
  • 35 Skinner JR. et al . Pulmonary and systemic arterial pressure in hyaline membrane disease.  Arch Dis Child. 1992;  67 366-373
    CrossrefPubMedGoogle Scholar
  • 36 Soll RF. Current trials in the treatment of respiratory failure in preterm infants.  Neonatology. 2009;  95 368-372
    CrossrefPubMedGoogle Scholar
  • 37 Speer CP. Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia.  Neonatology. 2009;  95 353-361
    CrossrefPubMedGoogle Scholar
  • 38 Speer CP. Surfactantsubstitutionstherapie. Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener.  Monatsschr Kinderheilkd. 2002;  150 659-668
    CrossrefPubMedGoogle Scholar
  • 39 Srisuparp P. et al . Inhaled nitric oxide therapy in premature infants with mild to moderate respiratory distress syndrome.  J Med Assoc Thai. 2002;  85 S469-S478
    PubMedGoogle Scholar
  • 40 Su PH, Chen JY. Inhaled nitric oxide in the management of preterm infants with severe respiratory failure.  J Perinatol. 2008;  28 112-116
    CrossrefPubMedGoogle Scholar
  • 41 Subhedar NV. et al . Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants.  Arch Dis Child Fetal Neonatal Ed. 1997;  77 F185-F190
    CrossrefPubMedGoogle Scholar
  • 42 Thomas W. et al . Airway concentrations of angiopoietin-1 and endostatin in ventilated extremely premature infants are decreased after funisitis and unbalanced with bronchopulmonary dysplasia/death.  Pediatr Res. 2009;  65 468-473
    CrossrefPubMedGoogle Scholar
  • 43 Truffert P. et al . for the Franco-Belgian iNO Study Group. Early inhaled nitric oxide in moderately hypoxemic preterm and term newborns with RDS: the RDS subgroup analysis of the Franco-Belgian iNO Randomized Trial.  Eur J Pediatr. 2003;  162 646-647
    CrossrefPubMedGoogle Scholar
  • 44 Van Meurs KP. et al . Inhaled nitric oxide for premature infants with severe respiratory failure.  NEJM. 2005;  353 13-22
    CrossrefPubMedGoogle Scholar
  • 45 Van Meurs KP. et al . Inhaled nitric oxide in infants >1 500 g and <34 weeks gestation with severe respiratory failure.  J Perinatol. 2007;  27 347-352
    CrossrefPubMedGoogle Scholar
  • 46 Wink DA. et al . Mechanisms of the antioxidant effects of nitric oxide.  Antioxid Redox Signal. 2001;  2 203-213
    PubMedGoogle Scholar
  • 47 Wirbelauer J, Speer CP. Die Inhalation von Stickstoffmonoxid in der Neonatologie: Stellenwert dieser Therapie im Jahre 2004.  Z Geburtsh Neonatol. 2004;  208 79-90
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Wirbelauer J, Speer CP. The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome (ARDS).  J Perinatol. 2009;  29 ((S 2)) 18-22
    CrossrefPubMedGoogle Scholar
  • 49 Zupancic JA. et al . Economic evaluation of inhaled nitric oxide in preterm infants undergoing mechanical ventilation.  Pediatrics. 2009;  epub ahead off print
    Google Scholar

Korrespondenzadresse

Dr. Johannes Wirbelauer

Universitäts-Kinderklinik

Universitätsklinikum Würzburg

Josef-Schneider-Str. 2

97080 Würzburg

Phone: +49 931-20127728

Fax: +49 31-20127242

Email: wirbelauer_j@klinik.uni-wuerzburg.de

      >